Cancer Treatment Reviews

Papers
(The TQCC of Cancer Treatment Reviews is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
Editorial Board240
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review229
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty224
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in166
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis146
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials138
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives121
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer109
Transformation from EGFR-mutant lung adenocarcinoma to small-cell lung cancer: from clonal evolution to lineage reprogramming88
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer83
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer83
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)81
FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma79
De-escalation strategies with targeted therapies in non-small cell lung cancer78
Editorial Board77
Opportunities and challenges for non–small cell lung cancer brain metastases in the immunotherapy era74
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches71
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?67
Surgical tumor volume reduction in patients with brain metastases: A systematic review and meta-analysis66
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev.64
If it’s a target, it’s a pan-cancer target: Tissue is not the issue64
Emerging antibody-based therapies for the treatment of acute myeloid leukemia63
First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features62
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis61
Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications60
Emerging mechanisms of triple-negative breast cancer radioresistance: Interplay between cancer cell mechanisms and the tumor immune microenvironment57
Optimizing care in early phase cancer trials: The role of palliative care56
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC56
Editorial Board52
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials52
Uncertainties and controversies in axillary management of patients with breast cancer51
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck48
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes48
Editorial Board48
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?47
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations47
CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation44
Editorial Board43
Combining antibody-drug conjugates with immune checkpoint inhibitors: A new paradigm for breast cancer therapy43
Corrigendum to “The importance of education and training in neuroendocrine neoplasms: challenges and opportunities for multidisciplinary management”. [Cancer Treat. Rev. 139 (2025) 102998]43
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment43
Extracellular vesicles and the “six Rs” in radiotherapy43
Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: A systematic review and meta-analysis42
Overview of BH3 mimetics in ovarian cancer42
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review42
The immunogram of inflammatory breast cancer41
Managing strategies of chemotherapy and radiotherapy-induced oral mucositis41
Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design41
HER-2 directed therapies across gastrointestinal tract cancers – A new frontier41
Optimizing outcomes and personalizing care with targeted agents in advanced cholangiocarcinoma39
Deciphering primary acinic cell carcinoma of the Breast: Insights from a comprehensive case series and Systematic review38
How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers38
Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis38
Long-term surveillance recommendations for young adult cancer survivors38
De-escalation of axillary irradiation for early breast cancer – Has the time come?36
Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada36
The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives35
Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma35
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)35
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features35
Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities34
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside34
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer34
Assessing lung function in women treated for breast cancer with radiotherapy. A comprehensive systematic review and meta-analysis33
Systematic review of the CUP trials characteristics and perspectives for next-generation studies33
Editorial Board33
Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review33
Angiogenesis and thymic epithelial tumors: from preclinical insights to different therapeutic lines and combination strategies33
Agnostic drug development revisited32
Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer32
Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies31
Immunocytokines in cancer treatment: A systematic review31
Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life30
Bone complications of cancer treatment30
Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review30
Malignant ascites: Current therapy options and treatment prospects30
Editorial Board29
Editorial Board29
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers29
Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes28
Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review27
Acknowledgement to Reviewers 202127
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications27
Genomic distinctions in adolescent and young adult cancer: A comprehensive review27
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?27
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?26
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review26
Local control strategies for management of NSCLC with oligoprogressive disease26
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis26
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review26
Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review25
Effectiveness of immune checkpoint inhibitor therapy in thyroid cancer: A systematic review25
Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification24
Evolving immunotherapeutic solutions for triple-negative breast carcinoma24
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project24
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges24
Chemotherapy in pancreatic ductal adenocarcinoma: When cytoreduction is the aim. A systematic review and meta-analysis24
Corrigendum to “T-cell engager toxicity in clinical phase trials; A systematic review and meta-analysis”. [Cancer Treat Rev. 139 (2025) 102991. doi: 10.1016/j.ctrv.2025.102991]24
Engineering strategies to optimise adoptive cell therapy in ovarian cancer24
Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives23
Does the benefit of neoadjuvant chemotherapy at six months predict long-term outcomes in colon or rectal cancer? A meta-analysis of randomised studies23
PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence23
Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312]23
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer22
Review: Targeting EZH2 in neuroblastoma22
Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic revie22
Patient-reported outcome measure to implement routine assessment of cancer survivors’ unmet needs: An overview of reviews and COSMIN analysis22
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis21
Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases21
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond21
Strategies for improving detection of circulating tumor DNA using next generation sequencing21
SELNET clinical practice guidelines for soft tissue sarcoma and GIST21
Pharmacotherapy for leptomeningeal disease in breast cancer21
Selecting systemic treatment for metastatic neuroendocrine tumors of the lung—current evidence and clinical implications21
Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progression21
Editorial Board20
Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies20
Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives20
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors20
Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis20
Identification of the PROMs used to assess ICI toxicities and HRQoL in patients receiving immune checkpoint inhibitor treatment in cancer care and their suitability: A systematic review20
Editorial Board20
Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis20
Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review20
0.66498017311096